Kuros Biosciences Ltd. · SIX:KURN
Kuros Biosciences — Non-Deal Roadshow (May 2022)
16 slides from Kuros Biosciences's roadshow presentation, May 4, 2022
Slide 1: Kuros Biosciences: The future of spinal fusions
Kuros Biosciences The future of spinal fusions
Slide 2: Disclaimer
Disclaimer This presentation is private and confidential, has been furnished to you solely for your information and may not be reproduced, redistributed or disclosed in any way, in whole or in part, directly or indirectly, in or into the United States or the United Kingdom, Canada, Australia, japan,
Slide 3: Investment highlights
Investment highlights The future of spinal fusions Kuros is on a mission to ease the burden ated pain th ri better spinal * — Swiss-headquartered biotech company with operations in the Spinal Fusions Bone Graft Market Bone Graft Market Netherlands and the USA. 2021 Value 2021": Value 2030" * — Liste
Slide 4: Spinal fusion surgery: the challenge & opportunity
Spinal fusion surgery The challenge & opportunity 5.895 CAGR The number of spinal fusion surgeries conducted worldwide is growing, ? Hence, surgeons, medical organizations and insurers are becoming more discerning about the products approved for these procedures. References: 1. Medtech 360 report "O
Slide 5: Spinal surgery: the total addressable biologics market
Spinal surgery: the total addressable biologics market Market 1 5 bn Global Global market Global market value (USD? |. Procedures'3 = 20211 20301 Bone grafts for 3.1 inal fusi 1m 2.4 bn $3.0 bn spinal fusion $24 bn $ ED .285y00.9 bn Insurers increasingly refuse claims for unproven and off-label prod
Slide 6: Spinal fusion surgery: two main types of surgery
Spinal fusion surgery Two main types of surgery Today's competitive landscape shows solutions that deliver high safety or efficacy... but rarely both. And none that are suitable for truly non-invasive surgical approaches. Bone graft is applied to the spine using minimally invasive access Reference:
Slide 7: Kuros solutions
Kuros solutions How do we address these two opportunities? r column Fibrin-PTH (KUR-113): Phase II MagnetOs: Launched The first ever investigational drug- biologic candidate to be evaluated for spinal fusion; and the first to be compatible with truly non-invasive surgical procedures. A bone graft th
Slide 8: In pursuit of the first drug-biologic combination for spinal fusion
In pursuit of the first drug-biologic combination for spinal fusion * Fibrin-PTH combines the wel-established mechanism of the bone growth factor parathyroid hormone (PTH) with the natural healing matrix known as fibrin.” * Once implanted, Fibrin-PTH promotes spinal fusion by increasing the number a
Slide 9: Fibrin-PTH Phase II: Design
Design STRUCTURE Fibrin-PTH Phase II: First drug-biologic candidate in trials for spinal fusion Treatment Primary endpoint Study sites and Pls Prospective, randomized controlled single blind multi- center study which intends to demonstrate safety and efficacy of Fibrin-PTH (KUR-113) versus local aut
Slide 10: MagnetOs compared with other bone grafts
4 ‘sats) MAGNETOS. NovaBone Putty® PA Vitoss® BADX bl Autograft >> https://kurosbio.com/magnetos/ References: 1. Duan, et al. eCM, 2019;37:60-73. 2. Van Dik, et al. eCM, 2021;41:756-73. 3. Van Dijk, et al. JOR Spine. 2018;21039.4. Van Dijk, et al | Biomed Mater Res. Part B: Appl Biomater. 2019;107(6
Slide 11: MagnetOs Case Report
MagnetOs Case Report Case courtesy of Dr. Alpesh A. Patel, Northwestern Memorial Hospital, Chicago, IL, USA. 60-year-old female Diagnosis: Procedure: Post-Operative Outcomes: Unstable fractures at C2 and C4 This patient underwent a 3-level posterior Post-Operative XRs and CTs show healed cervical th
Slide 12: Expand the depth and breadth of our commercial footprint
Expand the depth and breadth of our commercial footprint, by doubling our US sales team and expanding new territories United States ° Direct sales team that spans 50 states. * Supported by growing network of independent agents & distributors. * Sales in all major metropolitan areas. * Accounts inclu
Slide 13: Management overview
Management overview Executive Management Michael Grau Chief Finance Officer Joost de Bruijn Chief Executive Officer Extended Leadership Team John Griffin Charlie Campion SVP & President US Sales SVP Marketing & International Sales - Alistair Irvine Philippe Saudan Chief Business Officer Chief Develo
Slide 14: Strategic plan for growth: key value drivers
Strategic plan for growth: 4 key value drivers O 4 Expand depth and breadth of our commercial + 510(k) —MagnetOs Flex + CE mark Magnets footprint by doubling our US sales team and Regulatory Matrix Flex Matrix expanding new territories. eal + 510(k)—MagnetOs i Granules indication expansion Phase II
Slide 15: In summary...
In summary... The biggest crisis facing the healthcare economy is spine- related pain, with the number of procedures growing every year. Kuros is primed to meet this clinical need in both the anterior and posterior columns of the spine. We achieve this through superior biologics for spinal fusion, s
Slide 16: Thank you
Thank you